Zobrazeno 1 - 10
of 204
pro vyhledávání: '"L. Osgood"'
Autor:
Mirat Shah, Christy L. Osgood, Anup K. Amatya, Mallorie H. Fiero, William F. Pierce, Abhilasha Nair, Jonathan Herz, Kim J. Robertson, Bronwyn D. Mixter, Shenghui Tang, Richard Pazdur, Julia A. Beaver, Laleh Amiri-Kordestani
Publikováno v:
Clinical Cancer Research. 28:5249-5253
On July 26, 2021, the FDA granted approval to pembrolizumab in combination with chemotherapy for neoadjuvant treatment and then continued as a single agent for adjuvant treatment following surgery for patients with high-risk, early-stage triple-negat
Autor:
Patrick J. Grohar, Francisco Morís, Lee J. Helman, Javier González-Sabín, Luz-Elena Núñez, Mary E. Winn, Zachary B. Madaj, Lisa Turner, Malcolm Smith, Min Kang, Stephen L. Lessnick, Savita Sankar, Min He, Girma M. Woldemichael, Meti Gebregiorgis, Laura Segars, Susan Kitchen-Goosen, Christopher G. Kidd, Nichole Maloney, Christy L. Osgood
Purpose: The goal of this study was to identify second-generation mithramycin analogues that better target the EWS-FLI1 transcription factor for Ewing sarcoma. We previously established mithramycin as an EWS-FLI1 inhibitor, but the compound's toxicit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3d0749f76a543249a5b3ef28f63aea13
https://doi.org/10.1158/1078-0432.c.6523083.v1
https://doi.org/10.1158/1078-0432.c.6523083.v1
Autor:
Patrick J. Grohar, Francisco Morís, Lee J. Helman, Javier González-Sabín, Luz-Elena Núñez, Mary E. Winn, Zachary B. Madaj, Lisa Turner, Malcolm Smith, Min Kang, Stephen L. Lessnick, Savita Sankar, Min He, Girma M. Woldemichael, Meti Gebregiorgis, Laura Segars, Susan Kitchen-Goosen, Christopher G. Kidd, Nichole Maloney, Christy L. Osgood
Table S1, PCR primers used in gene signature panel. Table S2, Evidence for selection of each gene as an EWS-FLI1 target. S3A Mean fold change in expression of NR0B1 as a function of GAPDH (2Î"Î"CT) following treatment with MMA or EC-8105. Data is t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::41af203bf3e40e5edb0bf0c619f46fdf
https://doi.org/10.1158/1078-0432.22455681
https://doi.org/10.1158/1078-0432.22455681
Autor:
Melanie Royce, Christy L. Osgood, Anup K. Amatya, Mallorie H. Fiero, C.J. George Chang, Tiffany K. Ricks, Krithika A. Shetty, Jeffrey Kraft, Junshan Qiu, Pengfei Song, Rosane Charlab, Jingyu Yu, Kathryn E. King, Anshu Rastogi, Brian Janelsins, Wendy C. Weinberg, Kathleen Clouse, Vicky Borders-Hemphill, Lindsey Brown, Candace Gomez-Broughton, Zhong Li, Thuy Thanh Nguyen, Zhihao Qiu, Anh-Thy Ly, Suyoung Chang, Tingting Gao, Chi-Ming Tu, Bellinda King-Kallimanis, William F. Pierce, Kelly Chiang, Clara Lee, Kirsten B. Goldberg, John K. Leighton, Shenghui Tang, Richard Pazdur, Julia A. Beaver, Laleh Amiri-Kordestani
Publikováno v:
Clin Cancer Res
On December 16, 2020, the FDA granted regular approval to margetuximab-cmkb (MARGENZA), in combination with chemotherapy, for the treatment of adult patients with HER2-positive (HER2+) metastatic breast cancer who have received two or more prior anti
Autor:
Tatiana M. Prowell, Laleh Amiri-Kordestani, Joyce Cheng, Danielle Krol, Erik Bloomquist, Christy L. Osgood, Shenghui Tang, Gwynn Ison, Richard Pazdur, Rajeshwari Sridhara, Jennifer J Gao, Suparna Wedam, Melanie Royce, Julia A. Beaver
Publikováno v:
The Lancet Oncology. 22:1573-1581
Summary Background Cyclin-dependent kinase 4/6 inhibitors (CDKIs) are oral targeted agents approved for use in combination with endocrine therapy as first-line or second-line treatment of patients with hormone receptor-positive, HER2-negative, advanc
Autor:
Sara A. Hurvitz, Christy L. Osgood, Preeti Narayan, Laleh Amiri-Kordestani, Jennifer J Gao, Julia A. Beaver, Matthew P. Goetz, Danielle Krol, C.P. Miller, Meredith M. Regan, Erik Bloomquist, L. Mauro, Gwynn Ison, Fatima Cardoso, Brian Booth, C. Hodgdon, Vishal Bhatnagar, Richard Pazdur, Lola Fashoyin-Aje
Publikováno v:
Annals of Oncology. 32:950-953
Publikováno v:
The Neurohospitalist. :194187442311662
Background and Purpose The American Heart Association and American Stroke Association (AHA/ASA) strongly recommend specialty palliative care (PC) for all patients hospitalized with life-threatening or life-altering strokes to provide expert symptom m
Autor:
Mirat Shah, Daniel L. Suzman, Mallorie H. Fiero, Danielle Krol, Amna Ibrahim, Laleh Amiri-Kordestani, Soma Ghosh, Christina Brus, Gwynn Ison, Tatiana M. Prowell, Shenghui Tang, Reena Philip, Sakar Wahby, Melanie Royce, Shaily Arora, Tara Berman, Julia A. Beaver, Jennifer J Gao, Preeti Narayan, Richard Pazdur, Suparna Wedam, Erik Bloomquist, Christy L. Osgood
Publikováno v:
Clin Cancer Res
Over the last decade, there has been tremendous progress in the treatment of patients with gynecologic cancers with a changing therapy landscape. This summary provides an overview of U.S. Food and Drug Administration (FDA) approvals for gynecologic c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0dd0d59d29d17c905da03926e5cca53d
https://europepmc.org/articles/PMC8923904/
https://europepmc.org/articles/PMC8923904/
Autor:
Soma Ghosh, Willie Wilson, Pengfei Song, Laleh Amiri-Kordestani, Sherry Hou, Junshan Qiu, Hui Zhang, Richard Pazdur, Jeffrey D. Seidman, Julia A. Beaver, Reena Philip, Fatima Rizvi, Jennifer J Gao, Abde M. Abukhdeir, Vishal Bhatnagar, Yutao Gong, Haw-Jyh Chiu, Tiffany K. Ricks, Nam Atiqur Rahman, Paul G. Kluetz, William F. Pierce, Erik Bloomquist, Christy L. Osgood, Xiling Jiang, Jingyu Yu
Publikováno v:
Clinical Cancer Research. 27:2126-2129
On June 29, 2020, the FDA approved pertuzumab, trastuzumab, and hyaluronidase-zzxf subcutaneous injection (Phesgo) for the treatment of patients with HER2-positive early-stage and metastatic breast cancer. Patients should be selected for therapy base
Publikováno v:
Neurocritical Care. 33:533-541
Hypernatremia has been associated with mortality in neurocritically ill patients, with and without traumatic brain injury (TBI). These studies, however, lack concomitant adjustment for hyperchloremia as a physiologically co-occurring finding despite